Combination therapy of the H2712 murine mammary carcinoma with cytotoxic T lymphocytes and anti-estrogens

Anticancer Research

Volumn 17, Issue 5 A, 1997, Pages 3647-3651

  Baral, Edward ^a   Nagy, Eva ^b   Kangas, Lauri ^c   Berczi, Istvan ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c ORION CORPORATION   (Finland)

Author keywords

Anti estrogen; Cytotoxic T lymphocytes; Immunotherapy; Murine mammary carcinoma; Tamoxifen; Toremifene

Indexed keywords

ANTIESTROGEN; TAMOXIFEN; TOREMIFENE;

ANIMAL EXPERIMENT; ARTICLE; BREAST CARCINOMA; CANCER IMMUNOTHERAPY; CYTOTOXIC T LYMPHOCYTE; FEMALE; GROWTH INHIBITION; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; COMBINED MODALITY THERAPY; CYTOTOXICITY, IMMUNOLOGIC; ESTROGEN ANTAGONISTS; FEMALE; IMMUNOTHERAPY; INTERFERON TYPE II; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED C3H; SPLEEN; SURVIVAL ANALYSIS; T-LYMPHOCYTES, CYTOTOXIC; TAMOXIFEN; TOREMIFENE;

EID: 0030778451     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Kallio S, Kangas L, Blanco G, Johansson R, Karjalainen A, Perila M, Pippo I, Sundquist H, Sodervall M and Toivola R: A new triphenylethylene compound, Fc-1157a. I. Hormonal effects. Cancer Chemother Pharmacol 17: 103-108, 1986.
2. Kangas L, Nieminen A-L, Blanco G, Gionroos M, Kallio S, Karjalainen A, Perila M, Sodervall M and Toivola R: A new triphenylethylene compound, Fc-1157a. II. Antitumor effects. Cancer Chemother Pharmacol 17: 109-113, 1986.
3. Lerner LJ and Jordan VC: Development of antiestrogens and their use in breast cancer: 8th Cain memorial award lecture. Cancer Res 50: 4177-4189, 1990.
4. Paavonen T and Andersson LC: The oestrogen antagonists, tamoxifen and FC-1157a, display oestrogen like effects on human lymphocyte functions in vitro. Clin Exp Immunol 61: 467-474, 1985.
5. Valavaara R, Tuominen J and Toivanen A: The immunological status of breast cancer patients during treatment with a new antiestrogen, toremifene. Cancer Immunol Immunother: 31: 381-386, 1990.
6. Baral E, Nagy E and Berczi I: The effect of tamoxifen on the immune response. In: Tamoxifen: Beyond the Antiestrogen (Kellen JA, ed). Boston, Birkhauser, 1996, pp 137-178.
7. Baral E, Glas U, Rutquist LE and Skoog L: Adjuvant therapy in postmenopausal patients with operable breast cancer. In: Fundamental Problems in Breast Cancer. Amsterdam, M Nijhoff, 1987, p 335.
8. Nagy E, Berczi I and Sehon AH: Inhibition of the H2712 MTV positive mammary carcinoma in C3H/HeJ mice by murine monoclonal IgE anti-MTV antibodies. Cancer Immunol Immunother 34: 63-69, 1991.
9. Nagy E, Baral E, Kangas L and Berczi I: Anti-estrogens potentiate the immunotherapy of the P815 murine mastocytoma by cytotoxic T lymphocytes. Anticancer Res, 1997 (in press).
10. Laatikainen A: Immune response against P815x2 mastocytoma growing in syngeneic DBA/2 mice. Scand J Immunol 30: 479-455, 1989.
11. EORTC Breast Co-operative Group, Revision of the standards for the assessment of hormone receptors in human breast cancer; report of the second EORTC Workshop. Eur J Cancer 16: 1513-1515, 1980.
12. Pichon MF and Milgrom E: Characterization and assay of progesterone receptor in human mammary carcinoma. Cancer Res 37: 464-471, 1977.
13. Baral E, Nagy E and Berczi I: Enhancement of natural killer cell mediated cytotoxicity by tamoxifen. Cancer 75: 591-599, 1995.
14. Baral E, Nagy E, Kangas L and Berczi I: Immunotherapy of the SL2-5 murine lymphoma with natural killer cells and tamoxifen or toremifene. Anticancer Res 17: 77-84, 1997.
15. Baral E, Nagy E and Berczi I: Modulation of lymphokine-activated killer cellmediated cytotoxicity by estradiol and tamoxifen. Int J Cancer 66: 214-218, 1996.
16. Baral E, Nagy E, Kangas L and Berczi I: Anti-estrogens enhance the therapeutic effect of lymphokine activated killer cells on the P815 murine mastocytoma. Int J Cancer 67: 580-585, 1996.
17. Berczi I, Strausbauch P and Schon AH: Rejection of tumor cells in vitro. Science 180: 1289-1291, 1973.
18. Berczi I: Cancer immunology - Quo vadis? An overview. J Exp Clin Cancer Res 2: 135-144, 1983.
19. Berczi I, Nagy E and Baral E: The amplification of cell-mediated cytolysis by estradiol and tamoxifen. 8th International Congress of Immunology, August 23-28, 1992, Budapest, Hungary (Abstract), 1992.
20. Baral E and Vanky F: Effect of tamoxifen on cell-mediated autotumor lysis. J Clin Lab Immunol 22: 97-100, 1987.
21. Baral E, Nagy E and Berczi I: Target cells are sensitized for cytotoxic T-lymphocyte-mediated destruction by estradiol and tamoxifen. Int J Cancer 57: 1-5, 1994.
22. Teodorczyk-Injeyan J, Cembrzynska-Nowak M, Lalani S and Kellen JA: Modulation of biological responses of normal human mononuclear cells by antiestrogens. Anticancer Res 13: 279-283, 1993.
23. 14C-fluorodeoxyglucose content. Res Exp Med 189: 113-119, 1989.
24. Kangas L, Cantell K and Schellekens H: Additive and synergistic antitumor effects with toremifene and interferons. J Steroid Biochem 36: 259-262, 1990.
25. Young HA and Hardy KJ: Role of interferon-y in immune cell regulation. J Leukoc Biol 58: 373-381, 1995.